Skip to content

LT Pharma

Active Private limited companyfounded 2016active for 10 yearsRue de Robersart, Franière 29, 5150 FloreffeKBO/BCE: BE 0662.445.167 #8 company by total assets in Floreffe, Wholesale and retail trade sector

Annual accounts 2025

abbreviated format, filed on 31-10-2026, 92 days late
€208,046
€205,217
€152,451
-€229,872
11.3%
0.76

Turnover is estimated at about €980,000, probably between €640,000 and €2.1m.

Balance sheet

balance sheet total €1.5m on 31-12-2025
What the company ownsHow it is paid for

Position in the sector

11.3%

Higher than 20% of the 13,315 companies filing abbreviated accounts in retail trade (NACE 47) in 2025.

0.76

Higher than 15% of the 13,174 companies filing abbreviated accounts in retail trade (NACE 47) in 2025.

10.0%

Higher than 73% of the 13,235 companies filing abbreviated accounts in retail trade (NACE 47) in 2025.

LT Pharma Middle half of the sector 80% of the sector Abbreviated accounts in retail trade (NACE 47)

Net result: top quarter · Equity: middle half · Balance sheet total: middle half · Working capital: bottom quarter

Key figures and ratios

per financial year, computed from the annual accounts
Line Trend2025202320222021202020192018201716 months
206,697177,598180,905111,798249,557223,294--
153,931131,564133,61980,879181,964411,212--
-1,2327,4000029,807800,005-
--20,344360,416-81,374126,281123,68913,710-
-229,872811,262740,837674,524653,553531,495209,997-
11.3%66.4%61.3%55.2%49.1%41.7%19.2%100.0%
0.7613.1011.989.075.625.273.40-
7.820.510.630.811.041.404.20-
88.2%11.0%12.8%8.6%22.2%65.7%91.2%-
10.0%7.3%7.8%4.8%10.9%27.4%17.6%-
29.0918.8718.9410.84----

EBIT margin not included in this filing.

A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.

Filed annual accounts

as filed with the National Bank, click a year to choose it
Line Trend2025202320222021202020192018201716 months
Balance sheet: assets
20/58 1.5m1.7m1.6m1.6m1.6m1.5m1.1m18,600
21/28 802,193805,153812,586811,953817,906823,859800,005-
22/27 2,1455,10512,53811,90517,85823,811--
24 2,1455,10512,53811,90517,85823,811--
28 800,048800,048800,048800,048800,048800,048800,005-
29/58 723,702878,321808,296758,152794,894655,833297,65418,600
40/41 506,347297,141197,879499,564444,638420,967175,000-
40 505,425263,500174,800239,200197,500175,000--
41 92233,64123,079260,364247,138245,967175,000-
54/58 191,763540,978561,322200,906282,280155,99932,31018,600
490/1 25,59240,20249,09557,68267,97678,86790,344-
Balance sheet: equity and liabilities
10/49 1.5m1.7m1.6m1.6m1.6m1.5m1.1m18,600
10/15 172,9111.1m994,292867,440792,514616,503211,24418,600
10/11 18,60018,60018,60018,60018,60018,60018,60018,600
100 ----18,60018,60018,60018,600
13 1,8601,8601,8601,8601,8601,8601,860-
130/1 1,8601,8601,8601,8601,860---
130 ----1,8601,8601,860-
1311 1,8601,8601,8601,860----
14 152,4511.1m973,832846,980772,054596,043190,784-
17/49 1.4m566,283626,590702,665820,286863,189886,415-
17 379,410499,224559,131619,037678,945738,851798,758-
170/4 379,410499,224559,131619,037678,945738,851798,758-
42/48 953,57467,05967,45983,628141,341124,33887,657-
42 59,90760,58459,90759,90759,90759,90759,907-
44 -2,7942,0832,4633,6762,9697,000-
440/4 -2,7942,0832,4633,6762,9697,000-
45 143,9451,42464817,50968,53855,41220,750-
450/3 143,9451,42464817,50968,53852,89120,750-
454/9 -----2,521--
47/48 749,7222,2574,8213,7499,2206,050--
492/3 20,000-------
Income statement
9900 208,046179,422182,138113,214250,377224,19531,293-
630 1,4808,6656,7675,9535,9535,953--
640/8 1,3491,8241,2331,416820901347-
9901 205,217168,933174,138105,845243,604217,34130,946-
75/76B -----252,967175,000-
75 -----252,967175,000-
65/66B 7,1069,4139,55010,31611,11111,9948,354-
65 7,1069,4139,55010,31611,11111,9948,354-
9903 198,111159,520164,58895,529232,493458,314197,592-
67/77 45,66036,62137,73620,60356,48253,0554,948-
9904 152,451122,899126,85274,926176,011405,259192,644-
9905 152,451122,899126,85274,926176,011405,259192,644-
Appropriation of the result
9906 1.0m1.1m973,832846,980772,054596,043192,644-
14P 879,979973,832846,980772,054----
691/2 ------1,860-
6920 ------1,860-
694/7 879,979-------
694 879,979-------
Document PDFPDFPDFPDFPDFPDFPDFPDF

The full notes are in the accounts filed with the NBB.

Source: Annual accounts 2025 at the NBB, filed on 31-10-2026.

Filings

each dot is a set of accounts, on the day it reached the National Bank

The accounts were filed on 31-10-2026. The deadline was 31-07-2026, 7 months after the close on 31-12-2025 (article 3:10 of the Companies and Associations Code). Source: NBB, 2026-00598043.

Financial year Type Filed Reference Document
31-12-2025 abbreviated format 31-10-2026 2026-00598043 PDF
31-12-2023 full format 31-08-2024 2024-00458462 PDF
31-12-2022 full format 01-09-2023 2023-00440235 PDF
31-12-2021 micro format 31-08-2022 2022-20421814 PDF
31-12-2020 micro format 30-08-2021 2021-61900049 PDF
31-12-2019 micro format 31-12-2020 2020-77900595 PDF
31-12-2018 micro format 31-12-2020 2020-77900594 PDF
31-12-2017 micro format 31-08-2018 2018-62300185 PDF

Investments

fixed assets acquired
Item2025202320222021
Tangible fixed assets--€7,400-
€1,480€8,665€6,767€5,953

Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)

Insights on LT Pharma

The operating result for 2025 is €205,217, against €168,933 in 2023. Comparable figures for the intervening years are unavailable.

Debt's share of the balance-sheet total is 88.7%.

Next steps